News summaryViking Therapeutics Investor RelationsNov 15, 2026, 12:00 PM
Viking Therapeutics Highlights Clinical Data from VK2735 Obesity Program at ObesityWeek® 2026
VKTXpharmaceuticals
At ObesityWeek on Nov. 15, 2026, Viking reported a Phase 2 VENTURE analysis: after 13 weeks, 74% of participants receiving subcutaneous VK2735 improved by at least one BMI category, versus 15% on placebo; no VK2735-treated participant moved to a higher category. The analysis also found improvements across multiple cardiometabolic markers. Positive clinical update; no negative company-specific item